Liraglutide
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
Novo Nordisk · Phase 2 · Completed · Enrollment 957
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
- Placebo Sema 0.05 mg
- Placebo Sema 0.1 mg
- Placebo Sema 0.2 mg
- Placebo Sema 0.3 mg (fast dose escalation)
- Placebo Sema 0.4 mg (fast dose escalation)
- Placebo Lira 3.0 mg
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Sema 0.05 mg | n/r | n/r | n/r | n/r |
| Sema 0.1 mg | n/r | n/r | n/r | n/r |
| Sema 0.2 mg | n/r | n/r | n/r | n/r |
| Sema 0.3 mg | n/r | n/r | n/r | n/r |
| Sema 0.4 mg | n/r | n/r | n/r | n/r |
| Sema 0.3 mg (fast dose escalation) | n/r | n/r | n/r | n/r |
| Sema 0.4 mg (fast dose escalation) | n/r | n/r | n/r | n/r |
| Lira 3.0 mg | n/r | n/r | n/r | n/r |
| Placebo Sema 0.05 mg | 53.5% | 18.94% | n/r | n/r |
| Placebo Sema 0.1 mg | 67.49% | 36.57% | n/r | n/r |
| Placebo Sema 0.2 mg | 74.91% | 55.95% | n/r | n/r |
| Placebo Sema 0.3 mg | n/r | n/r | n/r | n/r |
| Placebo Sema 0.4 mg | n/r | n/r | n/r | n/r |
| Placebo Sema 0.3 mg (fast dose escalation) | 80.52% | 57.76% | n/r | n/r |
| Placebo Sema 0.4 mg (fast dose escalation) | 82.52% | 64.61% | n/r | n/r |
| Placebo Lira 3.0 mg | 66.12% | 33.98% | n/r | n/r |
Not shown
- Sema 0.05 mg: endpoint not reported
- Sema 0.1 mg: endpoint not reported
- Sema 0.2 mg: endpoint not reported
- Sema 0.3 mg: endpoint not reported
- Sema 0.4 mg: endpoint not reported
- Sema 0.3 mg (fast dose escalation): endpoint not reported
- Sema 0.4 mg (fast dose escalation): endpoint not reported
- Lira 3.0 mg: endpoint not reported
- Placebo Sema 0.3 mg: endpoint not reported
- Placebo Sema 0.4 mg: endpoint not reported